An Act to Improve Accountability and Understanding of Data in Insurance Transactions
LD 1906 creates new statutory rights for plan sponsors to obtain claims and payment data from health insurance administrators and pharmacy benefits managers, and to conduct audits of that data. The bill requires administrators and PBMs to provide specified claims, payment, rebate, fee, and related transaction information within set deadlines when a plan sponsor requests an audit, including special access to high-cost claims data over $100,000. It also allows plan sponsors to request post-payment audits at least once per calendar year, subject to timing limits, and bars administrators and PBMs from imposing audit restrictions or charging more than their direct costs to produce the data.
The bill also permits administrators and PBMs to require nondisclosure and data-use agreements that limit the auditor’s use of the information to the audit purpose, and it allows refusal of auditors who previously breached such agreements or refuse to sign them. The measure applies to new, amended, or renewed contracts on or after January 1, 2026, and violations are enforced exclusively under the Maine Unfair Trade Practices Act. It is framed as a transparency and accountability measure in insurance and prescription drug transactions, with a strong focus on data access, contract compliance, and audit rights.
The bill would add new provisions to Maine’s insurance code, including a new section in Title 24-A governing plan sponsor access to claims data and audit rights for both health coverage administrators and pharmacy benefits managers. It requires disclosure of detailed claims, payment, rebate, and fee information, limits contractual barriers to audits, and establishes enforcement through the Maine Unfair Trade Practices Act rather than separate administrative penalties. It also defines “plan sponsor” for these purposes and excludes certain insured employer plans from that definition, narrowing the bill’s reach in some employer-sponsored coverage arrangements.
The bill’s title and structure suggest a pro-transparency, pro-accountability approach, and the text is designed to give plan sponsors stronger oversight of claims processing and drug pricing arrangements. Because no committee transcripts or recorded votes were provided, there is no direct evidence of debate or opposition in the supplied materials. Based on the bill’s content, the likely general sentiment is favorable among supporters of cost oversight and audit access, especially employers and plan sponsors seeking more information about claims and PBM practices.
The main points of potential contention are the breadth of data disclosure, the burden on administrators and PBMs to produce detailed claims and payment information, and the limits placed on their ability to restrict audits or charge fees. Privacy and compliance concerns may arise because the bill requires disclosure of sensitive claims and medical record information, even though it conditions access on HIPAA-related certifications and nondisclosure agreements. Another likely issue is the bill’s impact on pharmacy benefits manager rebate and remuneration practices, which could be viewed as increasing transparency by plan sponsors but as exposing proprietary business information by administrators and PBMs.